could be exchanged or a liability settled between knowledgeable, willing parties in an arm's length transaction. 4. New policy on allowance for obsolete inventories Inventory from 1 year and above and
71.9 Allowance for the decline in value of inventory 2.2 0.9 150.6 12.4 3.9 219.9 Selling expenses 49.7 73.7 (32.6) 157.1 216.5 (27.4) Administrative expenses 38.8 38.0 2.1 98.0 142.5 (31.2) Foreign
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
Sales 9,643.6 10,351.4 9,933.1 Gross margin, (%) 20.3% 26.0% 30.0% Selling &Administration 1,612.8 1,804.3 1,817.6 Net Profit 934.5 2,014.9 -53.6% 2,544.5 -20.8% 7.7% 14.4% 17.9% The year 2019 continued
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
the year 2019 in an amounting of Baht (3.87) million or (10.39) percent. Mainly came from growth of revenue in last year while fixed cost still constant. 3.3 Administration expenses The Group's
155.70 million baht, an increase of 7.71 million baht or 5.2% from last year. The gross profit margin increased from 15.69% in 2018 to 17.54% in 2019. Sales and administration cost The company recorded
selling and general administration expensed for this quarter Please be informed accordingly. Yours sincerely Mr. Panya Boonyapiwat Chairman
of Accountancy from Chulalongkorn University, Thailand and a Master of Business Administration from Western Michigan University, USA. She has a wide range of experiences on capital market, including
approval and to provide convenient contact and inquiry channels in accordance with the Royal Decree on Rules and Procedures for Good State Administration. More information on the licensing manual is